

OMTN, Volume 22

## **Supplemental Information**

### **Circular RNA circRIMS1 Acts as a Sponge of miR-433-3p to Promote Bladder Cancer Progression by Regulating CCAR1 Expression**

**Feifan Wang, Mengjing Fan, Yueshu Cai, Xuejian Zhou, Shengcheng Tai, Yanlan Yu, Hongshen Wu, Yan Zhang, Jiaxin Liu, Shihan Huang, Ning He, Zhenghui Hu, and Xiaodong Jin**

**Table S1. The sequences of primers and oligonucleotides used in this study**

<b>Primers</b>	
circ-RIMS1 F	TACACACTGGAGCATAATGA
circ-RIMS1 R	AGAGTTATATTTTTCTTGTTCTGTT
Linear RIMS1 F	AGTTGTGGTATGATAAAGTGGGACA
Linear RIMS1 R	TTCGAGGACGTCCATCTACTCT
GAPDH F	GTCAAGGCTGAGAACGGGAA
GAPDH R	AAATGAGCCCCAGCCTTCTC
Myc F	GGCCCCAAGGTAGTTATCC
Myc R	GTTTCCGCAACAAGTCCTCTTC
Birc5 F	GACCCACTTATTTCTGCCACATC
Birc5 R	GAGTACAGAGGCTGGAGTGCATT
CCAR1 F	CTGATGGCTAGCCCTAGTATGGA
CCAR1 R	TGCCTTTCATGCCCACTAAAA
CEP135 F	AGTTTGAGAGGGTTGTGGTGG
CEP135 R	TGTATCCTTCTCGTGGGAGGT
NEGR1 F	CCTCTTAACCCTCCAAGTACAGC
NEGR1 R	CCAGCCATCAGCACTTTCAG
Hsa-miR-433-3p	ATCATGATGGGCTCCTCGGTGT
Hsa-miR-3064-5p	TCTGGCTGTTGTGGTGTGCAA
Hsa-miR-301b-5p	GCTCTGACGAGGTTGCACTACT
Hsa-miR-892b	CACTGGCTCCTTTCTGGGTAGA
Hsa-miR-6803-5p	CTGGGGGTGGGGGGCTGGGCGT
Hsa-miR-4268	GGCTCCTCCTCTCAGGATGTG
Hsa-miR-6852-5p	CCCTGGGGTTCTGAGGACATG
Hsa-miR-331-3p	GCCCCGGGCCTATCCTAGAA
Hsa-miR-4316	GGTGAGGCTAGCTGGTG
Hsa-miR-1468-5p	CTCCGTTTGCCTGTTTCGCTG
miRNA reverse	All-in-One miRNA qRT-PCR detection kit, GeneCopoeia, USA
<b>siRNAs Targeting sequence</b>	
Si circ-RIMS1 1#	CTTAGTCAAACAGAACAAGAA
Si circ-RIMS1 2#	GTCAAACAGAACAAGAAAAAT
Si circ-RIMS1 3#	TAGTCAAACAGAACAAGAAAA
Si CCAR1 1#	CCATCACTCCTTGGAGCAT
Si CCAR1 2#	CCACACAAACTCCAGCAA
Si CCAR1 3#	CCAGCAAATCAGTTAA
Si CEP135 1#	TGGGTGTATACCTATGTTAATGA
Si CEP135 2#	TTGGAAAGACATAAAGAAGAAGT
Si CEP135 3#	CAGCAGAAAGAGATAAACTAAGT
Si NEGR1 1#	CTGTTTCATCTATGATAGTCAACT
Si NEGR1 2#	TACAAGATTGTTGCAATTCAGA
Si NEGR1 3#	ATCAAGTTAAACCATACACTATC

<b>miRNAs mimics</b>	
Hsa-miR-433-3p sense	AUCAUGAUGGGCUCCUCGGUGU
Hsa-miR-433-3p anti-sense	UAGUACUACCCGAGGAGCCACA
Hsa-miR-301b-5p sense	GCUCUGACGAGGUUGCACUACU
Hsa-miR-301b-5p anti-sense	CGAGACUGCUCCAACGUGAUGA
Hsa-miR-1468-5p sense	CUCCGUUUGCCUGUUUCGCUG
Hsa-miR-1468-5p anti-sense	GAGGCAAACGGACAAAGCGAC
<b>Biotinylated probes</b>	
Biotin-circ-RIMS1	GTTATATTTTTCTTGTCTGTTTGACTAAGCTG
<b>Probes for RNA Fluorescence in situ hybridization</b>	
Hsa_circ_0132246-CY3	TTTTCTTGTCTGTTTGACTA
Hsa-miR-433-3p-FITC	ACACCGAGGAGCCATCATGAT

**Table S2. Detailed information of our own 20 bladder cancer patients is listed**

Patient number	Age at surgery	Gender	Grade	T	N	M	AJCC clinical stage
1	53	Male	High	T4b	N2	M0	4
2	67	Male	High	T4a	N1	M0	4
3	40	Male	High	T2b	N3	M0	4
4	52	Male	Low	Tis	N0	M0	Ois
5	58	Female	Low	Tis	N0	M0	Ois
6	59	Female	High	T1	N0	M0	1
7	78	Male	Low	Tis	N0	M0	Ois
8	81	Male	High	T1	N0	M0	1
9	68	Female	Low	Tis	N0	M0	Ois
10	66	Male	High	T1	N0	M0	1
11	68	Male	High	T2a	N0	M0	2
12	73	Male	High	T4b	N1	M0	4
13	61	Female	Low	Tis	N0	M0	Ois
14	62	Female	High	T2	N0	M0	2
15	68	Male	High	T1	N0	M0	1
16	84	Female	High	T2a	N0	M0	2
17	88	Male	High	Tis	N0	M0	Ois
18	86	Male	High	T2	N0	M0	2
19	84	Male	High	T2	N0	M0	2
20	48	Male	High	T2b	N0	M0	2

**Table S3. Correlation of circRIMS1 expression with clinicopathologic features of our own bladder cancer patients**

Characteristics	Number of cases	circRIMS1 expression in tumor tissue		P Value
		Low	High	
Age (year)				
<60	6	3	3	> 0.9999
≥60	14	7	7	
Gender				
Female	6	5	1	0.1409
Male	14	5	9	
T stage				
Tis-T <sub>1</sub>	10	8	2	<b>0.0230</b>
T <sub>2</sub> -T <sub>4</sub>	10	2	8	
N stage				
N0	16	10	6	0.0867
N <sub>1</sub> +N <sub>2</sub> +N <sub>3</sub>	4	0	4	
Grade				
Low	5	5	0	<b>0.0325</b>
High	15	5	10	

The bold P value is less than 0.05, which has statistically significant.

**Table S4. Detailed information of 60 bladder cancer cases for CCAR1 IHC assay**

Patient number	Age at surgery	Gender	Grade	T	N	M	AJCC clinical stage
1	76	Male	High	T2	N1	M0	4
2	67	Male	High	Tis	N0	M0	Ois
3	82	Male	High	T3	N0	M0	3
4	82	Male	High	T2	N0	M0	2
5	62	Male	High	T2	N0	M0	2
6	80	Male	High	T2	N0	M0	2
7	50	Male	High	T3	N0	M0	3
8	59	Male	High	T3	N0	M0	3

9	66	Male	High	T2	N0	M0	2
10	76	Male	High	T3	N0	M0	3
11	67	Male	High	T2	N0	M0	2
12	83	Male	High	T1	N0	M0	1
13	81	Male	Low	T2	N0	M0	2
14	75	Male	High	T3	N1	M0	4
15	71	Male	High	T4	N1	M0	4
16	75	Male	High	T3	N0	M0	3
17	72	Female	High	T2	N0	M0	2
18	66	Female	High	T2	N0	M0	2
19	67	Male	High	T2	N1	M0	4
20	58	Male	High	T1	N0	M0	1
21	77	Male	High	T1	N0	M0	1
22	68	Male	High	T3	N0	M0	3
23	61	Male	High	T1	N0	M0	1
24	58	Female	High	T3	N0	M0	3
25	73	Male	High	T1	N0	M0	1
26	42	Female	High	T3	N0	M0	3
27	57	Male	High	T2	N0	M0	2
28	55	Male	High	T3	N0	M0	3
29	75	Male	Low	T1	N0	M0	1
30	73	Male	High	T3	N0	M0	3
31	77	Male	High	T3	N1	M0	4
32	57	Male	High	Tis	N0	M0	Ois
33	78	Male	High	T1	N0	M0	1
34	74	Male	High	T1	N0	M0	1
35	72	Female	Low	Tis	N0	M0	Ois
36	65	Female	High	T3	N0	M0	3
37	59	Male	Low	T4	N0	M0	3
38	75	Male	High	T3	N0	M0	3
39	55	Male	High	T3	N0	M0	3
40	57	Male	High	T3	N0	M0	3
41	61	Male	High	T3	N1	M0	4
42	79	Male	High	T3	N0	M0	3
43	77	Male	High	T1	N0	M0	1
44	48	Male	High	Tis	N0	M0	Ois
45	72	Female	Low	Tis	N0	M0	Ois
46	85	Female	High	T3	N0	M0	3
47	76	Male	High	T1	N0	M0	1
48	61	Male	Low	T1	N0	M0	1
49	75	Male	High	Tis	N0	M0	Ois
50	66	Female	Low	Tis	N0	M0	Ois
51	84	Male	High	T3	N0	M0	3


52	75	Male	High	T2	N1	M0	4
53	78	Male	Low	Tis	N0	M0	Ois
54	44	Male	High	T3	N0	M0	3
55	77	Female	High	T3	N0	M0	3
56	71	Male	High	T3	N0	M0	3
57	62	Male	High	T2	N0	M0	2
58	59	Male	Low	T3	N0	M0	3
59	64	Male	Low	T2	N1	M0	4
60	67	Male	High	T1	N0	M0	1

**Table S5. Correlation of CCAR1 expression with clinicopathologic features of 60 bladder cancer patients**

Characteristics	Number of cases	CCAR1 expression in tumor tissue		P Value
		Low score	High score	
Age (year)				
<60	14	5	9	0.3604
≥60	46	25	21	
Gender				
Female	10	6	4	0.7306
Male	50	24	26	
T stage				
Tis-T <sub>1</sub>	20	15	5	<b>0.0127</b>
T <sub>2</sub> -T <sub>4</sub>	40	15	25	
N stage				
N <sub>0</sub>	52	27	25	0.7065
N <sub>1</sub>	8	3	5	
Grade				
Low	10	8	2	0.0797
High	50	22	28	

The bold P value is less than 0.05, which has statistically significant.


**Figure S1.** The efficiency of siRNAs for CCAR1, CEP135 and NEGR1 in T24 and EJ.




**Figure S1.** The efficiency of siRNAs for CCAR1, CEP135 and NEGR1 in T24 and EJ. **a-c** The alterations of CCAR1, CEP135 and NEGR1 in T24 and EJ cells stably transfected with N.C. or siRNAs were determined by western blotting respectively.

**Figure S2.** CCAR1 is regulated by miR-433-3p.

**a**



**b**



**Figure S2.** CCAR1 is regulated by miR-433-3p. **a.** The protein level of CCAR1 of bladder cancer cells transfected miR-433-3p sponge (or N.C. sponge) or pre-miR-433-3p (or N.C.) were respectively evaluated by western blotting. **b.** T24 and EJ cells were transfected with NC or sh-circRIMS1 or cotransfected with sh-circRIMS1 and miR-433-3p sponge. CCAR1 level was detected by western blotting.